Manufacturability is access: redesigning antibody production for equitable pediatric access in LMICs - Takeaways - MDSpire

Manufacturability is access: redesigning antibody production for equitable pediatric access in LMICs

  • By

  • Kerry R. Love

  • Stacy E. Martin

  • Laura Crowell Orella

  • May 18, 2026

  • 0 min

Share

  • 1

    Monoclonal antibodies (mAbs) are crucial for pediatric health but face accessibility issues in low- and middle-income countries (LMICs) due to high manufacturing costs.

  • 2

    Efforts to reduce the cost of mAb production aim for a target of less than US$10/g, but current optimized processes still exceed US$30/g.

  • 3

    Innovative mAb products like nirsevimab and CIS43LS show promise in preventing diseases like RSV and malaria in children, but high costs limit their use in LMICs.

  • 4

    Local manufacturing and process automation can transform LMICs from price takers to market makers, enhancing access to mAbs for pediatric patients.

  • 5

    Cost-effective mAb strategies require not only lower prices but also regionally adaptable products to address local health challenges and logistical barriers.

Original Source(s)

Manufacturability is access: redesigning antibody production for equitable pediatric access in LMICs

  • by Kerry R. Love, Stacy E. Martin, Laura Crowell Orella

  • May 18, 2026

Related Content

Flu Hospitalization Tied to Diabetes Risk

A large English cohort study found influenza hospitalization more than doubled the short-term risk of new-onset diabetes, with prediabetes and critical care admission among the strongest predictors.

Comparison of the therapeutic performance of macrolide antibiotics on macrolide-resistant or macrolide-susceptible Mycoplasma pneumoniae pneumonia children

Hydrocortisone May Lower Severe CAP Mortality

Network meta-analysis suggests hydrocortisone may offer mortality and ventilation benefits, although evidence certainty remained low.